Biologics dominate treatment costs for Crohn’s and ulcerative colitis

BIologic drug therapy makes up more than 70% of the total cost of care for either condition

October 19, 2019

Biologic therapy makes up more than 70% of the total cost of care for members with either Crohn’s disease (CD) or ulcerative colitis (UC)

Crohn’s disease and ulcerative colitis are the two major types of inflammatory bowel disease (IBD). This study determined that biologic therapy makes up most of the annual total pharmacy and medical costs. It shows real-world prevalence, utilization, and total health care costs to improve understanding of the conditions. It adds Prime’s insights to the industry dialogue tying drug cost to value. But it’s clear that it is not possible to obtain a direct medical care cost offset to biologic therapy in IBD.

Prevalence of Crohn’s Disease (CD) and Ulcerative Colitis (UC), Biologic Therapy Use, and Total Medical and Pharmacy Claims Expense Associated with CD and UC in a Population of 15 Million Commercially Insured Members (Spring 2019)

Related news

Perspectives

February 14, 2024

March 2024 decisions expected from the FDA

Your monthly synopsis of new drugs expected to hit the market

Perspectives

February 14, 2024

High-Cost Therapy Profile

Detailed information about Marnetegragene autotemcel Intravenous (IV)

Perspectives

February 14, 2024

Oncology Insights: Cancer treatments are making their way home

Many health care services provided in the hospital can be safely delivered in…